Who We Are
Our Company
Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing an antibody licensed from the University of Nebraska, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
INVESTEE COMPANIES.
- OncoQuest transferred its immunotherapy assets to OncoQuest Pharmaceuticals, Inc. (“OQP”) in return for convertible bonds and a corporate bond of OQP. The OQP bonds will be exchanged into bonds of Canaria Bio M and are planned to be exchangeable ultimately into shares of Canaria Bio. OncoQuest issued an in-kind dividend of OQP bonds to its shareholders on January 14, 2022. Quest, upon exchange of OQPB bonds to shares, will own about 23% of the Korean company that is developing immunotherapy assets.
- Quest has an 10.67 % direct ownership interest in OncoVent. Quest also has a 12% indirect interest through its ownership interest in OncoQuest. OncoQuest owns 29% of OncoVent.
